Choose Your Country or Region

Anti-BCRP/ABCG2 Rabbit Antibody [C19D24]

Catalog No.: F3762

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IHC1:4000 FCM1:100

Application
WB, IHC, FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
72 kDa 70 kDa, 75 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	Human placenta tissue; Human liver tissue; Human glioma tissue; Mouse liver tissue; Rat liver tissue; A549 (prepared in RIPA lysate buffer and was not boiled before loading); HepG2 (prepared in 1% SDS Hot Lysate buffer and boiled before loading)
Negative Control	A549 (prepared in RIPA lysate buffer and boiled before loading); Huh7 (prepared in 1% SDS Hot Lysate buffer and boiled before loading); HepG2

Datasheet & SDS

Biological Description

Specificity
BCRP/ABCG2 Rabbit mAb detects endogenous levels of total BCRP/ABCG2 protein.

Clone
C19D24

Synonym(s)
CD338, ABCP, BCRP, BCRP1, MXR, ABCG2, Broad substrate specificity ATP-binding cassette transporter ABCG2, ATP-binding cassette sub-family G member 2, Breast cancer resistance protein, CDw338, Mitoxantrone resistance-associated protein, Placenta-specific ATP-binding cassette transporter, Urate exporter

Background
Breast Cancer Resistance Protein (BCRP/ABCG2) is an ATP-binding cassette (ABC) transporter belonging to the G subfamily, encoded by the ABCG2 gene on chromosome 4q22. It is a half-transporter composed of a single nucleotide-binding domain (NBD) with conserved ATP-binding motifs (Walker A, Walker B, ABC signature) and a transmembrane domain (TMD) with six α-helices. ABCG2 functions as a homodimer or higher-order oligomer to form an active transporter. It features an extended extracellular loop between TM5 and TM6 and lacks a large intracellular coupling loop, both contributing to substrate recognition. BCRP mediates ATP-dependent efflux of a broad spectrum of substrates, including chemotherapeutics (mitoxantrone, topotecan), dietary compounds, toxins, uric acid, and porphyrins. It is highly expressed at physiological barriers and excretory tissues, such as the intestinal epithelium, liver canalicular membrane, kidney proximal tubules, placenta, mammary gland, and blood-brain barrier, where it limits xenobiotic absorption and promotes elimination. ABCG2 plays a major role in multidrug resistance in cancers by actively exporting drugs, complicating chemotherapy. Genetic polymorphisms, such as the Q141K variant, reduce ABCG2 function and are linked to hyperuricemia and gout.

Background

Breast Cancer Resistance Protein (BCRP/ABCG2) is an ATP-binding cassette (ABC) transporter belonging to the G subfamily, encoded by the ABCG2 gene on chromosome 4q22. It is a half-transporter composed of a single nucleotide-binding domain (NBD) with conserved ATP-binding motifs (Walker A, Walker B, ABC signature) and a transmembrane domain (TMD) with six α-helices. ABCG2 functions as a homodimer or higher-order oligomer to form an active transporter. It features an extended extracellular loop between TM5 and TM6 and lacks a large intracellular coupling loop, both contributing to substrate recognition. BCRP mediates ATP-dependent efflux of a broad spectrum of substrates, including chemotherapeutics (mitoxantrone, topotecan), dietary compounds, toxins, uric acid, and porphyrins. It is highly expressed at physiological barriers and excretory tissues, such as the intestinal epithelium, liver canalicular membrane, kidney proximal tubules, placenta, mammary gland, and blood-brain barrier, where it limits xenobiotic absorption and promotes elimination. ABCG2 plays a major role in multidrug resistance in cancers by actively exporting drugs, complicating chemotherapy. Genetic polymorphisms, such as the Q141K variant, reduce ABCG2 function and are linked to hyperuricemia and gout.

References
https://pubmed.ncbi.nlm.nih.gov/29061978/ https://pubmed.ncbi.nlm.nih.gov/29138424/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%